Jump to Navigation

Facebook Connect

User login

NLA to Host Free PCSK9 CME/CE Webinar Aug. 8

Join Dr. Carl Orringer from University of Miami and Dr. Alan S. Brown from Advocate Lutheran General Hospital on Tuesday, August 8th at 6:00pm EST to learn about the National Lipid Association's recommendations update on the use of PCSK9 inhibitors in your adult high-risk patients with ASCVD,... read more

Merck Provides Update on REVEAL Outcomes Study of Anacetrapib

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the... read more

JCL Impact Factor Rises to 5.812

The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015.

National Lipid Association Announces Recipients of Inaugural Junior Faculty Research Awards

The National Lipid Association (NLA) announced on Thursday the recipients of its inaugural Junior Faculty Research Awards for Clinical Science and Basic Science.

National Lipid Association Releases Results of Survey on Barriers to PCSK9 Inhibitor Prescription Approval Process

The National Lipid Association (NLA) released on Wednesday the results of its survey on the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor prescription approval process.

New York Lipidologist Becomes President of the National Lipid Association

The National Lipid Association (NLA) announced the election of new President James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, on Saturday at the 2017 Scientific Sessions in Philadelphia.

National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session

The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy made in the NLA Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 in 2015.

NLA Adds Trio of New Features to 2017 Scientific Sessions

With the National Lipid Association’s 2017 Scientific Sessions in Philadelphia from May 18-21 fast approaching, NLA members have an annual meeting packed full of top insights from respected medical leaders to look forward to.

by Dr. Radut.